Search Results - "Brannan, Sarah P"

Effect of Treatment for 12 Weeks With Rilapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, on Arterial Inflammation as Assessed With 18F-Fluorodeoxyglucose-Positron Emission Tomography Imaging by Tawakol, Ahmed, Singh, Parmanand, Rudd, James H.F., Soffer, Joseph, Cai, Gengqian, Vucic, Esad, Brannan, Sarah P., Tarka, Elizabeth A., Shaddinger, Bonnie C., Sarov-Blat, Lea, Matthews, Paul, Subramanian, Sharath, Farkouh, Michael, Fayad, Zahi A.

Get full text

Effect of Treatment for 12 Weeks With Rilapladib, a Lipoprotein-Associated Phospholipase A2Inhibitor, on Arterial Inflammation as Assessed With18F-Fluorodeoxyglucose-Positron Emission Tomography Imaging by Tawakol, Ahmed, Singh, Parmanand, Rudd, James HF, Soffer, Joseph, Cai, Gengqian, Vucic, Esad, Brannan, Sarah P, Tarka, Elizabeth A, Shaddinger, Bonnie C, Sarov-Blat, Lea, Matthews, Paul, Subramanian, Sharath, Farkouh, Michael, Fayad, Zahi A

“…[...]there are reasons to anticipate that a PET analysis that is limited to locations with evident structural atherosclerotic disease (i.e., a plaque-based…”
Get full text

Effect of Treatment for 12 Weeks With Rilapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, on Arterial Inflammation as Assessed With18 F-Fluorodeoxyglucose-Positron Emission Tomography Imaging by Tawakol, Ahmed, MD, Singh, Parmanand, MD, Rudd, James H.F., PhD, Soffer, Joseph, MD, Cai, Gengqian, PhD, Vucic, Esad, MD, Brannan, Sarah P., DPhil, Tarka, Elizabeth A., MD, Shaddinger, Bonnie C., PharmD, Sarov-Blat, Lea, PhD, Matthews, Paul, MD, Subramanian, Sharath, MD, Farkouh, Michael, MD, Fayad, Zahi A., PhD

Get full text